An increasing number of clinical trials show a successful outcome of chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies. This has resulted in multiple US Food and Drug Administration (FDA) approvals in the last few years. Flow cytometry has become an important tool in these clinical trials to monitor the presence and expansion of CAR T cells in patients. Immunophenotyping of CAR T cells by flow cytometry has provided valuable information to clinicians which helps to further improve the CAR T-cell therapy.
The featured speakers will discuss the role of flow cytometry in identifying the markers expressed on malignant plasma cells, which facilitates the selection of CAR T-cell therapy. Attendees will learn about the aspects of flow cytometry assays in CAR T-cell and plasma cell monitoring in multiple myeloma (MM) trials. In addition, the speakers will discuss the challenges of developing flow cytometry assays for clinical trials.
Join this webinar to learn the use of flow cytometry for the monitoring, phenotyping and characterization of CAR T cells in clinical trials.
Ans De Beuckelaer, Regional Head Flow Cytometry EU, Cerba Research
Ans De Beuckelaer has a PhD in science, biotechnology from the University of Ghent. In 2018, she joined Cerba Research as a Scientist in the flow cytometry department. After three years, she became the EU Regional Head of the Flow team, where Ans was involved in the development, validation and implementation of multiple flow assays for many global clinical trials.Message Presenter
Rowan Claeys, Clinical Pathologist, Cerba Research
Rowan Claeys graduated as a medical doctor and clinical pathologist from the University of Louvain. He worked in different hospital laboratories where he was responsible for medical validation in the field of laboratory hematology. Rowan was Head of Clinic in the hematology laboratory of the Laboratoire Hospitalier Universitaire de Bruxelles (LHUB) at the Erasme Hospital in Brussels, before joining Cerba Research in 2020 as a Clinical Pathologist in the flow cytometry department.Message Presenter
Who Should Attend?
Professionals from biotechs, mid pharmas, large pharmas or CROs including:
- Biomarker Leads
- Translational/Translational Medicine Biomarker Leads
- Clinical Biomarker Leads
- Clinical Development Directors/Medical Directors in CAR T
- Clinical Operations
- Clinical Trial Directors
- Clinical Trial Managers
- Purchasing, Director level and above
What You Will Learn
- CAR T-cell monitoring in multiple myeloma (MM) trials including:
- Flow assay design to monitor CAR T cells in patients
- Challenges in flow cytometry assay validation and testing in clinical trials
- Plasma cell monitoring in MM trials including:
- Multiple myeloma minimal residual disease (MM MRD) flow assay diagnostics and clinical endpoints
- Sensitivity comparison of minimal residual disease (MRD) assays: NGF (next-generation flow) vs. NGS (next-generation sequencing)
- Existing standard assays vs. customized assays for monitoring malignant cells
- The therapeutic impact on flow assays in monitoring plasma cells and CAR T cells
Cerba Research, a strategic provider of diagnostic solutions, supports drug development by leveraging patient data and scientific insight to optimize R&D and commercialization globally. Providing early phase research, clinical development through central laboratory and diagnostic testing, assay and biomarker development and validation — through our global network of specialty laboratories. We partner with government agencies, non-government organizations, as well as pharma and biotech organizations to change the shape of clinical development and advance healthcare. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.